stoxline Quote Chart Rank Option Currency Glossary
Vericel Corporation (VCEL)
43.74  -0.12 (-0.27%)    04-19 16:00
Open: 43.67
High: 44.5
Volume: 522,006
Pre. Close: 43.86
Low: 42.375
Market Cap: 2,116(M)
Technical analysis
2024-04-19 5:13:01 PM
Short term     
Mid term     
Targets 6-month :  57.19 1-year :  61.96
Resists First :  48.97 Second :  53.04
Pivot price 48.89
Supports First :  42.37 Second :  35.25
MAs MA(5) :  46.01 MA(20) :  49.1
MA(100) :  42.51 MA(250) :  37.59
MACD MACD :  -0.4 Signal :  0.4
%K %D K(14,3) :  6 D(3) :  8.4
RSI RSI(14): 33.1
52-week High :  53.04 Low :  29.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VCEL ] has closed above bottom band by 0.2%. Bollinger Bands are 58% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 44.57 - 44.88 44.88 - 45.12
Low: 41.58 - 41.99 41.99 - 42.31
Close: 43.16 - 43.73 43.73 - 44.17
Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 20 Apr 2024
Vericel CEO sells over $1.5m in company stock -

Fri, 19 Apr 2024
Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Shares - MarketBeat

Thu, 18 Apr 2024
DekaBank Deutsche Girozentrale Purchases Shares of 927 Vericel Co. (NASDAQ:VCEL) - Defense World

Sat, 13 Apr 2024
Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even - Yahoo Finance

Mon, 08 Apr 2024
Investors might be losing patience for Vericel's (NASDAQ:VCEL) increasing losses, as stock sheds 3.5% over the past ... - Simply Wall St

Sun, 03 Mar 2024
US$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 48 (M)
Shares Float 45 (M)
Held by Insiders 0.8 (%)
Held by Institutions 112.2 (%)
Shares Short 4,390 (K)
Shares Short P.Month 2,270 (K)
Stock Financials
EPS -0.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.71
Profit Margin -1.7 %
Operating Margin 19.5 %
Return on Assets (ttm) -1.3 %
Return on Equity (ttm) -1.6 %
Qtrly Rev. Growth 23.2 %
Gross Profit (p.s.) 0
Sales Per Share 4.08
EBITDA (p.s.) -0.04
Qtrly Earnings Growth 104.5 %
Operating Cash Flow 35 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -624.86
PEG Ratio 0
Price to Book value 9.26
Price to Sales 10.71
Price to Cash Flow 59.93
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android